No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 12, 2005, Pages 2862-2867

  Dorval, Michel ^a   Gauthier, Geneviève ^a   Maunsell, Elizabeth ^a   Dugas, Michel J ^b   Rouleau, Isabelle ^a   Chiquette, Jocelyne ^a   Plante, Marie ^a   Laframboise, Rachel ^a   Gaudet, Michel ^a   Bridge, Peter J ^c   Simard, Jacques ^a  

^a LAVAL UNIVERSITY   (Canada)

^b Gina Cody School of Engineering and Computer Science   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC COUNSELING; GERM LINE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; FEMALE; FRANCE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RISK;

EID: 30344455342     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0512     Document Type: Article

References (32)

1. Easton DF. How many more breast cancer predisposition genes are there? Breast Cancer Res 1999;1:14-7.
2. Thompson D, Easton D. The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004;9:221-36.
3. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004;4:850-60.
4. Houlston RS, Peto J. The search for low-penetrance cancer susceptibility alleles. Oncogene 2004;23:6471-6.
5. Simard J, Dumont M, Moisan AM, et al. Molecular Epidemiology of BRCA1 and BRCA2 mutations in French Canadian Breast/Ovarian Families. Toronto (Ontario): 54th Annual Meeting of the American Society of Human Genetics; 2004.
6. Carter RF. BRCA1, BRCA2 and breast cancer: a concise clinical review. Clin Invest Med 2001;24:147-57.
7. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997;277:997-1003.
8. McIntosh A, Shaw C, Evans G, et al. Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer. London: National Collaborating Centre for Primary Care/University of Sheffield; 2004.
9. Eisinger F, Bressac B, Castaigne D, et al. [Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004)]. Bull Cancer 2004;91:219-37.
10. Codori AM. Psychological opportunities and hazards in predictive genetic testing for cancer risk. Gastroenterol Clin North Am 1997;26:19-39.
11. Dorval M, Gauthier G, Maunsell E, Simard J, INHERIT BRCAs. Are women with an inconclusive BRCA1/2 genetic test result falsely reassured? Psychooncol 2003;12:166.
12. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003;21:2397-406.
13. Vezina H, Durocher F, Dumont M, et al. Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. Hum Genet 2005;117:119-32.
14. Godard B, Simard J; pour l'équipe INHERIT BRCAs, editors. Les enjeux éthiques de l'identification d'une susceptibilité génétique au cancer de sein dans un contexte de recherche clinique intégrée. Les pratiques de recherche biomédicale visitées par la bioéthique. Paris: Dalloz; 2003.
15. Avard D, Bridge P, Bucci L, et al. Partening in Oncogenetics Research-the INHERIT BRCAs experience: opportunities and challenges. Fam Cancer. In press.
16. Eisinger F, Alby N, Bremond A, et al. Expertise collective INSERM-FNCLCC: recommandations portant sur la prise en charge des femmes ayant un risque d'origine génétique de développer un cancer du sein et/ou de l'ovaire. Bull Cancer 1999;86:307-13.
17. Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer. N Engl J Med 2000;342:564-71.
18. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001;358:1389-99.
19. Beitman BD, Mukerji V, Lamberti JW, et al. Panic disorder in patients with chest pain and angiographically normal coronary arteries. Am J Cardiol 1989;63:1399-403.
20. Hallowell N, Richard MPM. Understanding life's lottery. An evaluation of studies of genetic risk awareness. In: Marks DF, editor. Journal of Health Psychology. London: SAGE Publication; 1997.
21. Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 1996;275:1885-92.
22. Bland JM. Sample size in guidelines trials. Fam Pract 2000;17 Suppl 1: S17-20.
23. Conover WJ, Iman RL. Analysis of covariance using the rank transformation. Biometrics 1982;38:715-24.
24. Statistical analysis system version 8.2. Cary (NC): The SAS Institute.
25. Hallowell N, Foster C, Ardern-Jones A, Eeles R, Murday V, Watson M. Genetic testing for women previously diagnosed with breast/ovarian cancer: examining the impact of BRCA1 and BRCA2 mutation searching. Genet Test 2002;6:79-87.
26. Schwartz MD, Peshkin BN, Hughes C, Main D, Isaacs C, Lerman C. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 2002;20:514-20.
27. Codori AM, Petersen G, Brensigner JD, Young C, Larkin EK, Bushey M. Inconclusive HNPCC test result unrealistically reduces colon cancer fear and risk perception. Ann Behav Med 1997;19:S177.
28. van Dijk S, Otten W, Timmermans DR, et al. What's the message? Interpretation of an uninformative BRCA1/2 test result for women at risk of familial breast cancer. Genet Med 2005;7:239-45.
29. Clausen H, Brandt NJ, Schwartz M, Skovby F. Psychological impact of carrier screening for cystic fibrosis among pregnant women. Eur J Hum Genet 1996;4:120-3.
30. Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in health postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-33.
31. Rouleau I, Chiquette J, Plante M, Simard J, Dorval M. Changes in health-related behaviours following BRCA1/2 genetic testing: the case of hormone replacement therapy. J Obstet Gynaecol Can 2004;26:1059-66.
32. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Genetic/familial high-risk assessment: breast and ovarian. Version 1, 2005 [cited 2005 September 11]. Available from: www.nccn.org/professionals/ physician_gls/PDF/genetics_screening.pdf.